This site is intended for US Healthcare Professionals only.


Browse the library of publications below for the latest research from ADC Therapeutics scientists.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study Caimi PF, et al. Haematologica. Aug 2023.
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial Hamadani M, et al. Blood Adv. Jan 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine Caimi PF, et al. eJHaem. Nov 2023
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021.
Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Chihara D, et al. Blood. Sep 2023.
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy Thapa B, et al. Blood Adv. Aug 2020.

Contact ADC Therapeutics

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at